Gaithersburg’s Emergent BioSolutions Inc. (NYSE: EBS) plans to begin “facility improvements” at its Baltimore manufacturing plant as Johnson & Johnson (NYSE: JNJ) assesses demand for its Covid-19 vaccine, which Emergent has been producing at that site. That’s what Emergent President and CEO Bob Kramer told analysts and investors on a fourth-quarter company earnings call Thursday.
Emergent BioSolutions to begin ‘improvements’ at Baltimore facility as J&J evaluates Covid vaccine demand
February 28, 2022
